« Previous
Next »
Comprehensive Psychiatry
Volume 45, Issue 1
, Pages 10-15
, January 2004
Insight in obsessive compulsive disorder and body dysmorphic disorder
References
- . Body dysmorphic disorder (the relationship to obsessive-compulsive disorder). J Nerv Ment Dis. 1990;178:538–540
- . Obsessive-compulsive disorder in relations to body dysmorphic disorder. Am J Psychiatry. 1992;149:1283–1284
-
.
Introduction.
In:
Hollander E editors. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Press; 1993;p. 95
-
.
Obsessive-compulsive spectrum disorders.
In:
Hollander E, Stein DJ editor. Obsessive-Compulsive Disorders. New York, NY: Marcel Dekker; 1997;p. 47–74
- . The obsessive compulsive spectrums. Psychiatr Clin North Am. 2002;25:791–809
- . Body dysmorphic disorder (the distress of imagined ugliness). Am J Psychiatry. 1991;148:1138–1149
- A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. J Clin Psychiatry. 2002;62:67–72
- . A comparison study of body dysmorphic disorder and obsessive-compulsive disorder. J Clin Psychiatry. 1998;59:568–575
- . Comparison of clinical characteristics in obsessive-compulsive disorder and body dysmorphic disorder. J Anxiety Disord. 1997;11:447–454
- . Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1207–1209
- . Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry. 2003;44:270–276
- . Pharmacologic treatment of body dysmorphic disorder (review of the evidence and a recommended treatment approach). CNS Spectrums. 2002;7:453–460
- . A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59:381–388
- Clomipramine vs desipramine crossover trial in body dysmorphic disorder (selective efficacy of a serotonin reuptake inhibitor in imagined ugliness). Arch Gen Psychiatry. 1999;56:1033–1039
-
.
Pharmacological management of obsessive-compulsive disorder (a review for clinicians).
Harvard Rev Psychiatry. 2002;10:127–137
- . Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995;52:53–60
- A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:922–927
- . Cognitive behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 1995;63:263–269
- Body dysmorphic disorder (a cognitive behavioural model and pilot randomized controlled trial). Behav Res Ther. 1996;34:717–729
-
.
Psychological treatment for obsessive-compulsive disorder.
In:
Mavisssakalian MR, Prien RF editor. Long-Term Treatments of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996;p. 285–309
-
Cognitive-behavior treatment of obsessive thoughts.
J Consult Clin Psychiatry. 1997;65:405–413
- . Dysmorphobia (body dysmorphic disorder or delusional disorder, somatic subtype?). Compr Psychiatry. 1989;30:457–472
- . Disorders with overvalued ideas. Br J Psychiatry. 1984;145:579–585
- . Dysmorphobia misdiagnosed as obsessive-compulsive disorder. Psychosomatics. 1990;31:220–222
- . The Brown Assessment of Beliefs Scale (reliability and validity). Am J Psychiatry. 1998;155:102–108
- . Characteristics of delusional experience. Eur Arch Psychiatry Neurol Sci. 1987;236:294–298
- . Dimensions of delusional experience. Am J Psychiatry. 1983;140:466–469
- Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry. 2001;42:494–497
- . The overvalued ideas scale (development, reliability, and validity in obsessive-compulsive disorder). Behav Res Ther. 1999;37:881–902
- . A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994;30:179–186
-
Diagnostic and Statistical Manual of Mental Disorders. Ed. 3. Rev.. Washington. DC: American Psychiatric Association; 1987;
-
Diagnostic and Statistical Manual of Mental Disorders. Ed. 4. Rev.. Washington, DC: American Psychiatric Association; 1994;
Washington
- . Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59:165–171
- The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Part I: Reliability. Arch Gen Psychiatry. 1989;46:1006–1011
- The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Part II: Validity. Arch Gen Psychiatry. 1989;46:1012–1016
- A severity rating scale for body dysmorphic disorder (development, reliability, and validity of a modified version of the Yale-Brown Obsessive-Compulsive Scale). Psychopharmacol Bull. 1997;33:17–22
-
.
Essentials of Behavioral Research (Methods and Data Analysis). Ed. 2. New York, NY: McGraw-Hill; 1991;
- . Obsessive-compulsive disorder with psychotic features (a phenomenological analysis). Am J Psychiatry. 1986;143:1527–1533
- . Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 2001;62:87–91
- . Obsessive-Compulsive Beliefs and Treatment Outcome. Psychol Med. 1988;18:697–702
-
.
Management of obsessive-compulsive rituals associated with delusions, hallucinations, and depression (a case report).
Behav Psychother. 1987;15:77–87
-
.
Failures in treating obsessive-compulsives.
Behav Res Ther. 1979;169–176
- . Feared consequences, fixity of belief, and treatment outcome in patients with obsessive-compulsive disorder. Behav Ther. 1999;30:717–724
☆ Supported in part by Pfizer Pharmaceuticals (J.L.E.) and by a National Institute of Mental Health grant (R29-MH54841) and an unrestricted grant from Solvay Pharmaceuticals and Pharmacia and Upjohn to K.A.P.
PII: S0010-440X(03)00172-X
doi: 10.1016/j.comppsych.2003.09.010
© 2004 Elsevier Inc. All rights reserved.
« Previous
Next »
Comprehensive Psychiatry
Volume 45, Issue 1
, Pages 10-15
, January 2004
